News

An expert discusses real-world data for ofatumumab (Kesimpta; Novartis), the first self-administered anti-CD20 monoclonal antibody, in patients with relapsing multiple sclerosis.

Here's what is coming soon to NeurologyLive.

The NeurologyLive staff compiled highlights from our discussions with experts in one convenient location, following ECTRIMS 2021.

In responding to complex cognitive tasks, the insomnia group had slower and more variable response latencies, produced fewer correct responses, and had more errors than normal sleepers.

Following the approval of 3 treatments for the disease, the clinical research director of the UCSF Multiple Sclerosis Center commented on the implications for the clinical development pipeline. [WATCH TIME: 4 minutes]

Jeffrey Bennett, MD, PhD, professor of neurology, University of Colorado, discussed his presentation at ECTRIMS involving the relationship of B-cell depletion and improved outcomes in patients treated with inebilizumab.

Investigators found that stress was likely to be the most modifiable risk factor.

Neurology News Network for the week ending October 23, 2021. [WATCH TIME: 3 minutes]

Discussing a 6-week, virtual program conducted over Zoom, the founder of First Coast Integrative Medicine, spoke on the use of telehealth and future research efforts for integrative medicine in MS. [WATCH TIME: 3 minutes]

This year, Teva is celebrating the 25th anniversary of the FDA approval of COPAXONE® (glatiramer acetate injection), but the story goes back much further. Hear what some of Teva's most prominent R&D leaders have to say about the history and origins of the treatment.

The trial provided Class IV evidence that VY-AADC01 and the associated surgical delivery procedure were well-tolerated in patients aged 40 to 70 years with moderately advanced Parkinson disease.

The professor of neurology at the NYU Grossman School of Medicine discussed his findings presented at ECTRIMS 2021, which did not support the hypothesis of a wearing off effect with ocrelizumab (Ocrevus; Genentech). [WATCH TIME: 4 minutes]

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Stephen Krieger, MD.

Chaired by Devon Conway, MD, the presentations also feature Cleveland Clinic experts Kedar Mahajan, MD, PhD; Marisa McGinley, DO; and Amy Kunchok, MD. [WATCH TIME: 1 hour, 33 minutes]

Despite projections that aducanumab (Aduhelm; Biogen) would be widely adopted in clinical practice after its June 2021 approval, financial reports suggest a different story. Jessica Zwerling, MD, MS, and Lon Schnider, MD, MS, offered their perspectives on its clinical application thus far.

Data from a recent study suggest that symptoms of potential obstructive sleep apnea influence this mediation.

The duo from MedStar Georgetown University Hospital detailed the need for education on Parkinson disease and movement disorder therapies, and the CME activities they’ve developed with the PMD Alliance to address those needs. [WATCH TIME: 5 minutes]

Deborah Miller, PhD, commented on strategies to maintain patient-provider communication following the discontinuation of disease-modifying therapies in MS.

The founder of First Coast Integrative Medicine spoke on a 6-week virtual program that introduced IM modalities, including guided journaling, nutrition, and yoga. [WATCH TIME: 3 minutes]

Just about two-thirds of patients remained on cenobamate throughout the entire analysis period and almost 40% had complete seizure reduction for at least 12 consecutive months at some time during the study.

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers spoke to the importance of utilizing palliative care principles in the regular care of Parkinson disease. [WATCH TIME: 7 minutes]

The PMD Alliance has developed a group of 6 on-demand CME events and live panel discussions, in partnership with MedStar Georgetown University Hospital, taking place on October 23-24, 2021, developed and presented by Yasar Torres-Yaghi, MD , and Fernando Pagan, MD.

Findings from the phase 3 REST-ON trial of the investigational sodium oxybate formulation show treatment improves sleep latency response and cataplexy response in patients with narcolepsy.

Ashish Pradhan, MD, the executive director and disease area lead for MS and NMOSD, Genentech, offered insight on a number of presentations at the 2021 ECTRIMS Congress.

Discussing this year’s virtual ECTRIMS conference, the Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University provided his opinion on recent developments in the MS field. [WATCH TIME: 3 minutes]

Investigators found that women with early-onset myasthenia gravis display distinct clinical features in contrast with men with the same condition, who are more like patients with late-onset MG of both sexes.

The professor of neurology at the NYU Grossman School of Medicine provided context on the preliminary data evaluating antibody response in ocrelizumab-treated patients post-vaccine. [WATCH TIME: 5 mintues]

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the realistic outlook of mesenchymal stem cells and other approaches to progressive MS.